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Role of cognitive factors in symptom induction following
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Background and aims: Dietary fat plays a role in the pathophysiology of symptoms in functional
dyspepsia (FD). In healthy subjects, cognitive factors enhance postprandial fullness; in FD patients,
attention increases gut perception. We hypothesised that the information given to patients about the fat
content of a meal would affect dyspeptic symptoms.
Methods: Fifteen FD patients were each studied on four occasions in a randomised double blind fashion.
Over two days they ingested a high fat yoghurt (HF) and over the other two days a low fat yoghurt (LF). For
each yoghurt, the patients received the correct information about its fat content on one day (HF-C, LF-C)
and the opposite (wrong) information on the other day (HF-W, LF-W). Dyspeptic symptoms, plasma
cholecystokinin (CCK) concentrations, and gastric volumes were evaluated.
Results: Both the fat content and information about the fat content affected fullness and bloating scores—
both were higher after HF-C compared with LF-C, and LF-W compared with LF-C, with no differences
between HF-C and HF-W. Nausea scores were higher after HF compared with LF, with no effect of the
information about fat content. No differences between discomfort and pain scores were found between
study conditions. Plasma CCK and gastric volumes were greater following HF compared with LF, with no
effect of the information given to the patients. All differences are p,0.05.
Conclusions: Cognitive factors contribute to symptom induction in FD. Low fat foods may also elicit
symptoms if patients perceive foods as high in fat, while CCK and gastric volumes do not appear to be
affected by cognitive factors.
T
here is growing evidence that nutrients, particularly fat,
play an important role in the pathophysiology of
functional dyspepsia (FD).1–4 Many patients with FD
report that their symptoms are exacerbated after ingestion of
foods containing fat. Ingestion of a high fat soup induces
more severe symptoms than the same soup without fat.3
Moreover, duodenal fat infusion results in a dose related
increase in the severity of dyspeptic symptoms in these
patients.5 This effect appears to be specific for fat as only
duodenal infusion of fat, but not glucose, induces the
symptomatic response.6
A number of mechanisms may, at least in part, mediate the
effects of fat on dyspeptic symptoms. Fat may act indirectly
via changes in gastrointestinal motility, for example through
an increase in proximal gastric relaxation.7 However, our data
suggest that duodenal lipid induces symptoms independently
of any changes in proximal gastric motor function;5 8
increasing the dose of duodenal fat is associated with an
increase in the severity of symptoms while the increase in
proximal gastric volume is not related to the fat dose. In
contrast, fat digestion is required for the induction of
‘‘dyspeptic’’ symptoms in healthy subjects,9 and the bene-
ficial effect of the cholecystokinin (CCK)-A receptor antago-
nist dexloxiglumide on symptoms induced by duodenal fat
infusion during gastric distension in patients with FD
suggests that CCK is also involved.5 As these factors do not
entirely explain the symptoms, other factors need to be taken
into consideration. These include other gastrointestinal
peptides and psychological factors, among others; their
contribution to symptom development after food ingestion,
particularly in relation to fat, in FD is unknown.
Cognitive factors play a role in appetite regulation; in
healthy subjects, a nutrient containing soup induces a greater
perception of fullness when subjects are informed of the
nature of the soup compared with the control condition in
which the subjects are not explicitly given this information.10
In patients with FD, both attention (due to anticipatory
knowledge) and distraction (by performance of a mental
task) modulate perception of duodenal distension; attention
increases and distraction attenuates gut perception.11 It is
therefore conceivable that FD patients respond with symp-
toms to certain foods as a result of a previous negative
learning experience or information they have received; the
possibility that even foods with a low fat content may
increase symptoms if patients perceive them as high in fat
has not been evaluated.
The aim of our study was therefore to evaluate in patients
with FD the role of cognitive factors on symptom induction,
proximal gastric motor function, and plasma CCK concentra-
tions in response to high fat and low fat yoghurts. We
investigated the hypothesis that the information given to the




Fifteen patients (nine women, six men; aged 24–56 years
(median 42)) with FD participated in the study. All patients
were of normal body weight for height (body mass index 22.8
(0.9) kg/m2), non-smokers, and did not take any medication
during the course of the study. The study was carried out
with the approval of the ethics committee at the University
Hospital Zu¨rich. All patients gave their informed written
consent prior to participation. Patients were recruited by
advertisement in local newspapers describing the symptomatic
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Abbreviations: FD, functional dyspepsia; CCK, cholecystokinin; VAS,
visual analogue scale; MDP, minimal distending pressure
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criteria required for entry into the study. In a telephone
interview, patients were selected for further investigation
depending on the presence and severity of symptoms.
Patients had at least three of the following symptoms for
more than six months of at least a moderate severity:
postprandial fullness/early satiety, bloating, epigastric pain,
and nausea/vomiting. Severity was scored on a 0–3 scale
with 0 representing ‘‘symptoms not experienced’’, 1 ‘‘slight
symptoms, but not bothering’’, 2 ‘‘moderate symptoms,
bothering, but not impairing daily activities’’, and 3 ‘‘severe
symptoms, impairing daily activities’’. Patients who had
previously undergone gastrointestinal surgery or were on
medications that could not be discontinued for the
duration of the study were not included. Each patient
underwent laboratory tests, upper gastrointestinal endo-
scopy, abdominal ultrasound, a 13C-urea breath test for
Helicobacter pylori status, and a H2 breath test to assess
lactose intolerance. If all investigations were negative,
patients were admitted into the study. Each subject was
required to visit the laboratory once before the start of the
study. During this visit, subjects were familiarised with
the requirements of the study, the gastric (barostat) tube,
the study procedures, and the symptom questionnaires.
Methods
Test meals
Two yoghurts (weight 300 g each) were used as test meals.
The low fat yoghurt (LF) consisted of 150 g fat free yoghurt,
75 g low fat milk, and 75 g raspberries (143 kcal, energy
from fat 8.1% (1.3 g), from carbohydrate 63.6% (21.6 g), and
from protein 28.3% (9.8 g)). The high fat yoghurt (HF)
consisted of 75 g whole fat yoghurt, 75 g cream, 75 g whole
fat milk, and 75 g raspberries (330 kcal, energy from fat
66.6% (23.6 g), from carbohydrate 23.5% (18.5 g), and from
protein 9.9% (8.0 g)). The ingredients were blended with an
electric mixer to obtain a thick consistency for both yoghurts.
Both yoghurts were appetising, and of similar taste,
consistency, and colour. Prior to administration to patients,
samples of both yoghurts were given to 16 healthy subjects in
a randomised order and immediately following each other to
test for palatability and whether subjects noticed any
differences, including sweetness, fat content, taste, or acidity
between the two yoghurts. All subjects rated both shakes as
very palatable, and five subjects did not notice a difference
between the yoghurts. The remaining 11 subjects indicated
that the yoghurts differed with regard to their sweetness
(seven subjects), fat content (two subjects), taste (eight
subjects), and acidity (five subjects). None of the subjects
was able to correctly assign fat content to the appropriate
yoghurt.
Gastric tube and barostat
Changes in gastric volume in response to the test meals were
evaluated in seven (four women, three men) of the 15
patients (the other eight patients did not tolerate the barostat
tube, as revealed during the prestudy visit). For this purpose,
each patient was intubated with a single lumen tube (OD
3.5 mm, ID 2.8 mm; Tygon Tubing, Upchurch Scientific, Oak
Harbor, Washington, USA), which had a flaccid thin walled
polyethylene bag (capacity 1100 ml) attached to its distal
end. The proximal end of the tube was connected via a three
way tap to the measurement and balloon ports of a gastric
barostat (Distender Series II; G&J Electronics Inc.,
Willowdale, Ontario, Canada). Functioning of the barostat
has been described in detail elsewhere.7 In brief, it is capable
of measuring changes in gastric volume at a fixed pressure.
Thus when the gastric wall relaxes, air is injected into the
gastric bag to maintain the pressure while air is withdrawn
when the stomach contracts. The barostat bag was positioned
in the fundus of the stomach, as described previously.2 The
bag was unfolded by inflating it with air, positioned in the
fundus by gently pulling the tube back until its passage was
restricted by the lower oesophageal sphincter, and then
pushed back in by 3 cm. The tubes were then secured to the
side of the face. Subjects tolerated the tubes well and did not
sense the empty bag in the stomach.
Blood sampling
Venous blood samples were taken repeatedly throughout the
study (fig 1) to determine plasma levels of CCK at baseline
and following meal ingestion. Samples were collected in
chilled EDTA tubes, centrifuged at 2 C˚ for 15 minutes, and
stored at 270 C˚ until extraction. Plasma CCK was deter-
mined by a sensitive and specific commercially available
radioimmunoassay kit (Euro-Diagnostica BV, Arnhem, the
Netherlands). Cross reactivity with sulphated gastrins was
0.5%, while cross reactivity with unsulphated gastrins was
,0.01%. The sensitivity of the assay was 0.3 pmol/l with a
confidence limit of 2 SD. The coefficients of variation were
5.5% at 4.4 pmol/l and 2.0% at 20.6 pmol/l for the intra-assay
variation, and 13.7% at 4.2 pmol/l and 4.1% at 20.6 pmol/l for
interassay variation.
Assessment of symptoms
The severity of postprandial fullness, bloating, epigastric
discomfort, pain, and nausea was assessed by means of
previously validated visual analogue scales (VAS)12 at base-
line and repeatedly after meal ingestion (fig 1). The VAS was
a 10 cm line, with 0 representing ‘‘sensation/symptom not
present’’ and 10 ‘‘sensation/symptom extremely strong/
uncomfortable’’.
Experimental protocol
Each patient was studied on four separate occasions. All
studies were carried out in the morning after an overnight
fast, 5–10 days apart, and each study took approximately
three hours. Patients who underwent the barostat study were
intubated, and the minimal distending pressure (MDP) was
determined first by raising intrabag pressure with the
barostat in steps of 1 mm Hg/min. MDP has previously been
defined as the pressure that is necessary to overcome intra-
abdominal pressure resulting in a bag volume of at least











Figure 1 Experimental protocol. Patients ingested a high fat or a low fat
yoghurt (each on two occasions; on one occasion patients were correctly
informed about the fat content of the yoghurt—that is, ‘‘this is a high fat
yoghurt’’ or ‘‘this is a low fat yoghurt’’, respectively—while on the other
occasion subjects were given the wrong information—that is, ‘‘this is a
low fat yoghurt’’ or ‘‘this is a high fat yoghurt’’, respectively. Patients
(n = 15) rated dyspeptic symptoms (including bloating, fullness, nausea,
and discomfort, pain) at regular intervals and blood samples for
determination of plasma cholecystokinin concentrations were taken at
the same time points. In addition, changes in gastric volume in response
to the four study conditions were recorded in seven of the 15 patients
using an electronic barostat. MDP, minimal distending pressure
(‘‘baseline’’ pressure).
Cognitive factors, fat, and dyspeptic symptoms 1415
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(t =220 minutes) and the corresponding volume was
monitored until a stable recording was obtained for at least
10 minutes (baseline, t =210 minutes). Then patients
ingested the test meal within 10 minutes (end of yoghurt
ingestion: t = 0 minutes), each yoghurt on two occasions.
The two occasions differed with regard to the information the
patients received about the composition of the yoghurt. On
one occasion, patients received the correct information
regarding the fat content of the yoghurt (that is ‘‘you will
now be invited to eat a high fat yoghurt’’ in the case of the
high fat yoghurt (condition HF-C) or ‘‘you will now be
invited to eat a low fat yoghurt’’ in the case of the low fat
yoghurt (condition LF-C)); on the other occasion they
received the wrong information (that is, ‘‘you will now be
invited to eat a low fat yoghurt’’ in the case of the high fat
yoghurt (condition HF-W) or ‘‘you will now be invited to eat
a high fat yoghurt’’ in the case of the low fat yoghurt
(condition LF-W)), in a standardised fashion, and patients
were presented with the empty containers of the ingredients.
In the seven patients with the barostat tube in place,
monitoring of gastric volume continued for two hours, and
in all patients blood samples were drawn and symptoms
assessed at regular intervals—that is, fasting (baseline)
samples at t =220, and 210 min, post-meal samples
immediately after meal ingestion (t = 0 min), and then every
five minutes for the first 20 minutes, every 10 minutes for
the subsequent 40 minutes, and every 20 minutes for the
final 60 minutes (until t = 120 minutes).
Data analysis
Changes in gastric volume during the different study
conditions were calculated by averaging the volume readings
obtained during the baseline period (at MDP +2 mm Hg) and
during consecutive 10 minute periods following meal inges-
tion. Data obtained at t =220 and 210 minutes for the
different parameters (VAS scores, plasma CCK concentra-
tions, gastric volumes) were then averaged to obtain a
baseline value. As these values varied slightly between study
conditions, they were adjusted using study day LF-C as a
reference, and then entered into the analysis.
Statistical analysis
Data were analysed using repeated measures analysis of
variance (two way ANOVA) with time and treatments as
factors. A p value ,0.05 was considered statistically




Scores for fullness increased following ingestion of all
yoghurts (p = 0.0001). Both the fat content of the yoghurt
and the information given to the subjects as to the fat content
of the yoghurts tended to affect ratings for fullness
(p = 0.067). Scores for fullness were higher following
ingestion of the high fat yoghurt compared with the low fat
yoghurt (HF-C v LF-C; p = 0.041). The information given to
subjects as to the fat content of the yoghurt markedly
affected scores for fullness following ingestion of the low fat
yoghurt; subjects felt significantly more full when told that
the yoghurt was high in fat (LF-C v LF-W; p = 0.013) while
the information given to the subjects did not increase the
severity of fullness following ingestion of the high fat yoghurt
any further (HF-C v HF-W; p = 0.803). In contrast, there was
no difference in scores for fullness between the high fat
yoghurt when subjects were told it was low in fat and the low
fat yoghurt when subjects were told it was high in fat (HF-W
v LF-W; p = 0.474).
Bloating (fig 2B)
Bloating scores increased following ingestion of all yoghurts
(p = 0.0001). Both the fat content of the yoghurt and the
information given to the subjects as to the fat content of the
yoghurts affected ratings for bloating (p = 0.038). Scores for
bloating were higher following ingestion of the high fat
yoghurt compared with the low fat yoghurt (HF-C v LF-C;
p = 0.042). The information given to subjects as to the fat
content of the yoghurt affected scores for bloating following
ingestion of the low fat yoghurt; subjects tended to feel more
bloated when told that the yoghurt was high in fat (LF-C v
LF-W; p = 0.056). In contrast, the information given to the
subjects did not increase the severity of bloating following
ingestion of the high fat yoghurt any further (HF-C v HF-W;
p = 0.412).
Nausea (fig 2C)
Ratings for nausea were slightly higher following ingestion of
the high fat yoghurt when subjects were informed that the
yoghurt was high in fat compared with the low fat yoghurt
when subjects were informed that the yoghurt was low in
fat (HF-C v LF-C; p = 0.012). In contrast, the information
given to subjects did not affect nausea ratings within the
type of yoghurt (HF-C v HF-W (p = 0.716); LF-C v LF-W
(p = 0.176)).
Discomfort
Scores for discomfort increased following ingestion of all
yoghurts (p = 0.001). However, there was no difference in
scores between the four study conditions (p = 0.165).
Pressure/pain
Pain scores increased only slightly following ingestion of all
yoghurts (p = 0.001) but there was no difference in scores
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Figure 2 Scores for fullness (A), bloating (B), and nausea (C) following ingestion of a high fat (HF) or a low fat (LF) yoghurt with patients receiving
either the correct (that is, ‘‘this is a HF yoghurt’’ or ‘‘this is a LF yoghurt’’, respectively) or the wrong (that is, ‘‘this is a LF yoghurt’’ or ‘‘this is a HF
yoghurt’’, respectively) information with regard to the fat content of the yoghurts. Data are means of n = 15 patients.
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Plasma CCK concentrations
Both yoghurts increased plasma CCK concentrations
(p = 0.0001) but the high fat yoghurt increased plasma
CCK more than the low fat yoghurt (HF-C v LF-C; p = 0.036).
Plasma CCK concentrations did not differ whether subjects
were given the correct or wrong information as to the fat
content of the yoghurt, although levels tended to be higher
during condition HF-correct (HF-C) compared with condition
HF-wrong (HF-W) (fig 3).
Gastric volume changes
Gastric volumes increased following ingestion of both
yoghurts (p = 0.001), except for condition LF-C (fig 4). In
addition, gastric volumes were greater following ingestion of
the high fat yoghurt compared with the low fat yoghurt (HF-
C v LF-C; p = 0.012). The information about the fat content of
the yoghurt did not significantly affect gastric volumes.
DISCUSSION
Our data demonstrate that: (1) cognitive factors contribute to
exacerbation of symptoms, particularly fullness, in FD, (2)
symptoms after ingestion of a low fat meal are particularly
affected by cognitive factors, while (3) plasma CCK concen-
trations and gastric volumes appear to be unaffected by
cognitive factors. In addition, our data confirm previous
reports that a high fat meal induces greater dyspeptic
symptoms and results in greater plasma CCK concentrations
and gastric volumes than a low fat meal.
The most interesting and novel finding of our study is that
some of the most frequent dyspeptic symptoms, fullness and
bloating, are exacerbated not only by ingestion of a meal high
in fat but also by a meal that is perceived by the patients as
high in fat. This has not been demonstrated previously and
indicates that the situation with regard to the role of fat in
dyspeptic symptom induction is more complex than assumed
previously.6 Our data therefore suggest that at least two
factors are involved in the induction of dyspeptic symptom
related to fat: (1) the actual fat content of the meal—
symptoms were more severe following the high fat yoghurt
compared with the low fat yoghurt; and (2) the perceived fat
content of the meal—patients associate fat ingestion with the
occurrence of symptoms and, as a result, experience them.
The mechanism(s) underlying this phenomenon is unknown.
It has been described previously that anticipatory knowledge
of gut distension enhances perception of this stimulus in
patients with FD,11 and awareness of the nutrient content of a
soup increases the feeling of fullness in healthy subjects.10
These previous findings indicate that the occurrence of
symptoms in patients with FD may perhaps be the result of
some form of conditioning due to the experience of
exacerbation of symptoms after ingestion of fatty foods in
the past. These previous findings also indicate that cognitive
factors influencing perception related to food ingestion occur
in both healthy subjects and in patients with FD. The
substantial effect of placebo treatment on symptom improve-
ment of up to 50%,13 14 which in some studies was similar to
the effect of the drug under study,13 is well documented in
patients with FD. This effect appears to occur independently
of any changes in gastrointestinal motility or gastric
perception,15 and a reduction in anxiety, as a result of the
patient’s belief that the treatment will relieve symptoms, has
been discussed as a possible underlying mechanism.15 It is
therefore conceivable that this effect is reversed in a situation
in which patients are confronted with a food, which they
perceive as having detrimental effects on their symptoms, as
in our study. Certainly, further studies are required to
investigate these findings in more detail as an understanding
of the role of cognitive factors may potentially provide
opportunities for novel therapeutic approaches. In contrast,
symptoms following the high fat yoghurt were not affected
by the information about the fat content. This may indicate
that the fat contained in the yoghurt per se had a dominant
independent effect on symptoms that could not be further
modulated by cognitive factors—that is, the cognitive
influence was weaker than the effect of fat.
The observation that patients with FD may also experience
symptoms after ingestion of low fat foods as a result of
cognitive influences, and not only after ingestion of foods
containing fat, raises the question as to the value of dietary
modification—for example, the adoption of a low fat diet—in
the management of dyspeptic symptoms apparently related
to fat ingestion. This may be particularly relevant in patients
in whom cognitive effects are suspected to have a major
influence on symptoms, and suggests that cognitive-
behavioural training may be a therapeutic strategy in patients
that complain of symptoms associated with eating, or
ingestion of specific foods, but are refractory to dietary
modification.
In considering underlying pathophysiological mechanisms,
studies in both humans and experimental animals have
demonstrated marked effects of somatic and mental stress




























Figure 3 Plasma cholecystokinin (CCK) concentrations following
ingestion of a high fat (HF) or low fat (LF) yoghurt with patients receiving
either the correct (that is ‘‘this is a HF yoghurt’’ or ‘‘this is a LF yoghurt’’,
respectively) or the wrong (that is, ‘‘this is a LF yoghurt’’ or ‘‘this is a HF
yoghurt’’, respectively) information with regard to the fat content of the
























Figure 4 Gastric volumes following ingestion of a high fat (HF) or low
fat (LF) yoghurt with patients receiving either the correct (that is, ‘‘this is a
HF yoghurt’’ or ‘‘this is a LF yoghurt’’, respectively) or the wrong (that is,
‘‘this is a LF yoghurt’’ or ‘‘this is a HF yoghurt’’, respectively) information
with regard to the fat content of the yoghurts. Data are means of n = 7
patients.
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addition, it has been suggested that plasma concentrations of
some gastrointestinal peptides, including CCK and somato-
statin, are significantly more elevated in response to a
stressful interview in patients with FD compared with
healthy subjects.21 We were unable to find differences in
postprandial plasma CCK concentrations or gastric volumes
(as a measure of gastric relaxation) in relation to the
information about fat content. Our data indicate that CCK
is not involved in exacerbation of symptoms by cognitive
influences. While plasma CCK concentrations tended to be
higher, although not statistically significant, when patients
were informed that the yoghurt was high in fat, the severity
of symptoms did not differ between the two high fat study
conditions. Therefore, our data do not provide evidence that
CCK is involved in symptom induction related to the
perceived fat content of a meal. The role of other gastro-
intestinal peptides or stress related hormones, including
corticotropin releasing factor,22 may warrant further investi-
gation. In addition, while our data suggest that proximal
gastric relaxation does not play a role in the exacerbation of
symptoms by cognitive influences, the lack of a statistically
significant difference may be the result of a type 2 error and
warrants further investigation.
In conclusion, our data provide evidence for a role of
cognitive factors in symptom induction in functional
dyspepsia, particularly after ingestion of low fat meals if
patients perceive them as containing high fat quantities,
while CCK and gastric volumes do not appear to be affected
significantly by cognitive factors. Our findings may have
important clinical implications and strongly suggest that
cognitive influences need to be taken into consideration in
the treatment of functional dyspepsia.
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LETTERS
If you have a burning desire to respond to a
paper published in Gut, why not make use
of our ‘‘rapid response’’ option?
Log onto our website (www.gutjnl.com),
find the paper that interests you, and send
your response via email by clicking on the
‘‘eLetters’’ option in the box at the top right
hand corner.
Providing it isn’t libellous or obscene, it
will be posted within seven days. You can
retrieve it by clicking on ‘‘read eLetters’’ on
our homepage.
The editors will decide as before whether
to also publish it in a future paper issue.
Ghrelin and Helicobacter pylori
We read with interest the article by Nwokolo
et al reporting raised serum ghrelin levels
following Helicobacter pylori eradication (Gut
2003;52:637–40). There are some exceptions
to the interpretation of the data that we
would take.
The authors state that the increase in
ghrelin levels seen in their study ‘‘lends
support to the view that ghrelin could be
involved in the long term regulation of body
weight’’. While there is growing evidence to
support this in the literature,1–3 this study
does not present any such data and is not
methodologically geared towards address-
ing this question. The proposal that eradica-
tion of H pylori leads to an increase in ghrelin
levels, which in turn leads to an increase in
obesity, is also without foundation. The only
known situation in which hyper-ghrelinae-
mia is associated with obesity is in Prader-
Willi syndrome.4 In all other studies ghrelin
levels correlate inversely with measures of
body adiposity, and are altered in a compen-
satory manner by changes in body weight.5
To suggest therefore that H pylori eradication
leads to a hyper-ghrelinaemic state that
drives increased appetite is not physiologi-
cally feasible as any transient appetite
increase would be expected to be countered
by any increase in adiposity, which in turn
would suppress ghrelin levels.
The authors’ proposal that ‘‘children with
H pylori may have relatively low ghrelin
concentrations contributing to growth retard-
ation’’ is also without foundation. A recent
study has shown H pylori status to have no
effect on ghrelin levels.6 The role of ghrelin on
the growth of children remains unclear.
Ghrelin is an endogenous ligand to the
growth hormone secretagogue receptor
(GHS-R), and potently stimulates growth
hormone release. It may indeed have a role
to play in growth, as in patients with a
genetic growth hormone releasing hormone
deficiency nocturnal enhancement of growth
hormone secretion remains,7 an effect that
may be mediated by ghrelin.
One other proposal of the authors is that
H pylori eradication increases 24 hour gastric
acidity by a ghrelin dependent mech-
anism. While central and peripheral ghrelin
administration has been shown to increase
stomach acidity when given to rats,8 data are
lacking in humans. The small but statistically
significant increase in acidity seen here
would be expected after H pylori eradication,
and is likely to be secondary to parietal cell
recovery following resolution of inflamma-
tion. The suggestion that hypergastrinaemia
leads to lower ghrelin levels, and vice versa, is
not supported in the literature.9
C D R Murray, A V Emmanuel
St Mark’s Hospital, Watford Road, Harrow,
Middlesex, UK
Correspondence to: Dr C D R Murray;
charlie.murray@talk21.com
References
1 Cummings DE, Weigle DS, Frayo RS, et al.
Plasma ghrelin levels after diet-induced weight
loss or gastric bypass surgery. N Engl J Med
2002;346:1623–30.
2 Nakazato M, Murakami N, Date Y, et al. A role
for ghrelin in the central regulation of feeding.
Nature 2001;409:194–8.
3 Wren AM, Seal LJ, Cohen MA, et al. Ghrelin
enhances appetite and increases food intake in
humans. J Clin Endocrinol Metab 2001;86:5992.
4 Cummings DE, Clement K, Purnell JQ, et al.
Elevated plasma ghrelin levels in Prader Willi
syndrome. Nat Med 2002;8:643–4.
5 Hansen TK, Dall R, Hosoda H, et al. Weight loss
increases circulating levels of ghrelin in human
obesity. Clin Endocrinol (Oxf) 2002;56:203–6.
6 Gokcel A, Gumurdulu Y, Kayaselcuk F, et al.
Helicobacter pylori has no effect on plasma
ghrelin levels. Eur J Endocrinol 2003;148:423–6.
7 Maheshwari HG, Pezzoli SS, Rahim A, et al.
Pulsatile growth hormone secretion persists in
genetic growth hormone-releasing hormone
resistance. Am J Physiol Endocrinol Metab
2002;282:E943–51.
8 Masuda Y, Tanaka T, Inomata N, et al. Ghrelin
stimulates gastric acid secretion and motility in rats.
Biochem Biophys Res Commun 2000;276:905–8.
9 Dornonville DLC, Bjorkqvist M, Sandvik AK, et al.
A-like cells in the rat stomach contain ghrelin and
do not operate under gastrin control. Regul Pept
2001;99:141–50.
Authors’ reply
We would like to draw the attention of Drs
Murry and Emmanuel to the objectives set
out clearly in the introductory section of our
paper.
Our study was not designed to address the
question of whether ghrelin is involved in
long term regulation of body weight.
Furthermore, the duration of the study was
too short to see any change in body mass
index. More importantly, waist circumfer-
ence would be a better anthropometric
measure of change in body fat composition
supported by sequential dual energy x ray
absorptiometry or magnetic resonance ima-
ging. The results of our study were unex-
pected and there was nothing in the literature
that gave us forewarning. We would have
designed the study to follow up the subjects
for at least one year, monitoring their plasma
ghrelin, and assessing changes in body com-
position using the techniques described above.
The authors refer to ‘‘physiological feasi-
bility’’ and thereby miss the point that Helico-
bacter pylori infected stomachs exhibit distor-
tion of normal physiological mechanisms. For
example, the tight reciprocal relationship
between gastrin and intragastric acidity seen
in H pylori negative subjects is modified in H
pylori positive subjects. We believe that a H
pylori infected stomach produces less ghrelin,
leading to decreased appetite and food
intake. The physiological response should be
that the resulting weight loss leads to a
compensatory increase in ghrelin, increased
appetite, and weight gain, and so on. We
believe that this ‘‘physiological’’ mechanism
is altered by the presence of H pylori, possibly
by resetting a putative ‘‘ghrelin thermostat’’
at a lower level, allowing thinness and hypo-
ghrelinaemia to occur together. Proof will
come only from further experimentation.
The authors cite a study comparing spot
measurements of plasma ghrelin in women
with and without H pylori gastritis;1 this does
not amount to a robust challenge to our
hypothesis on H pylori, ghrelin, and children.
The authors repeat the widely held although
unproven belief that the increase in intragas-
tric acidity after H pylori cure can be
attributed to recovery of parietal cells from
inflammation. They ignore our observation of
a positive correlation between ghrelin and
24 hour intragastric acidity. We accept that
the relationship between gastrin and ghrelin
is unproven in humans but this emphasises
the paucity of human data and the need for
more studies.
C U Nwokolo, H Randeva
University Hospitals, Coventry and Warwickshire NHS
Trust, Clifford Bridge Rd, Coventry CV2 2DX, UK
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Helicobacter pylori, ghrelin, and
obesity
Nwokolo et al have demonstrated that follow-
ing eradication of Helicobacter pylori from
asymptomatic patients, plasma ghrelin
‘‘increases profoundly’’ (Gut 2003;52:637–
40). Although we find these results interest-
ing, we cannot agree with the conclusion that
this may be causally linked to epidemiologi-
cal observations of the rising incidence of
obesity and oesophageal adenocarcinoma in
Western populations. In particular, the pre-
sent study in fact demonstrates that after H
pylori eradication, ghrelin merely returns to
levels detected in non-obese control patients
using the same hormone assay.1 It would
seem likely that H pylori infection, leading to
oxyntic gland atrophy,2 is associated with at
most a mild suppression of plasma ghrelin,
which recovers after treatment. This seems
unlikely to have a profound effect on calorie
intake, particularly as obese patients have a
lower mean plasma ghrelin concentration
than matched non-obese controls.1 While it
is possible, although unproven, that the
virtual abolition of plasma ghrelin seen after
roux-en-Y gastric bypass surgery may contri-
bute to the paradoxical reduction in hunger
Gut 2004;53:315–316 315
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observed in these patients, it is simplistic to
suggest that the moderate reduction in
ghrelin, as seen in the H pylori infected group
in this study, is protective against the develop-
ment of obesity and its associated conditions.
R C Macadam, V Borse, I Dodo, S G Pollard
St James’ University Hospital, Level 8, Clinical
Sciences Building, Leeds LS9 7TF, UK
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Author’s reply
Macadam et al have rightly questioned
whether our novel observation is merely
epiphenomenal or of pathophysiological sig-
nificance. Their ‘‘gut feeling’’ is that it is the
former as the changes are ‘‘mild’’ and ghrelin
concentrations after Helicobacter pylori cure are
no different from those seen in a non-obese
Western population. They also suggest that
the ‘‘moderate’’ reduction of ghrelin in H
pylori positive subjects (which they attribute
to oxyntic gland atrophy) is unlikely to
protect these individuals from obesity.
There is no doubt that cure of H pylori
increases plasma ghrelin in ‘‘healthy sub-
jects’’. The real questions are: whether
plasma ghrelin concentrations are higher in
H pylori negative individuals and, if so,
whether the higher ghrelin concentrations
cause weight gain, and whether any weight
gained exacerbates gastro-oesophageal acid
reflux enough to induce Barrett’s oesophagus
and cancer. There are no satisfactory answers
to these questions based on first class
evidence but in our discussion, we considered
some indirect evidence. Firstly, populations
with a high prevalence of H pylori have a
relatively high proportion of thin children
and adults, and those with a low prevalence
have a higher proportion of obese individuals;
we acknowledge the numerous other con-
founding factors in our paper.
Secondly, Furuta et al showed that patients
cured of H pylori gained weight.1 Lane et al,
continuing their reporting of the large Bristol
Helicobacter project, showed that at the end of
six months, individuals who received treat-
ment for H pylori increased their weight by
0.6 kg over and above a matched group that
received placebo.2 Finally, in the only pub-
lished study of its kind, infusion of ghrelin
into healthy subjects was associated with
increased appetite and food intake.3
In the presence of H pylori, abnormalities in
the function of the gastric neuroendocrine
cell population can be detected long before
gastric atrophy occurs. ‘‘Inappropriate’’
hypergastrinaemia and disturbances in D cell
function have been described; these are fully
reversible, returning to normal soon after H
pylori cure.4 5 Similarly, gastric atrophy which
is irreversible in the short term is unlikely to
be the mechanism that mediates hypo-
ghrelinaemia in H pylori positive subjects,
given that reversion to normal non-obese
concentrations occurred 6–12 weeks after
cure, which was the time course of our study.
Also, the median age of our subjects was
36 years; the fact that they had normal
gastrin concentrations and 24 hour intragas-
tric acidity makes it unlikely that they had
significant gastric atrophy.
In general, single factors rarely account for
large epidemiological trends. We do not
believe that everything can be explained by
ghrelin; that would really be simplistic.
However, we believe that H pylori positive
subjects with low ghrelin may have decreased
appetite and food intake and are thinner than
their H pylori negative counterparts in the
Western world. Their poor nutritional status
would be exaggerated by coexisting dyspepsia
due to peptic ulceration, concurrent infection,
and poor diet. They would have relatively
lower intragastric acidity. Taken together,
these factors could protect these individuals
from gastro-oesophageal reflux disease
(GORD). Conversely, having normal ghrelin,
a good appetite, and normal intragastric
acidity could make GORD more likely, possi-
bly leading to Barrett’s oesophagus and
oesophageal adenocarcinoma.
C U Nwokolo, H Randeva
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CORRECTION
In the paper by Feinle-Bisset et al (Gut 2003;
52: 1414–18), an author was missing from
the author list, listing only three of the
authors as C Feinle-Bisset, B Meier and M
Fried. In fact, there was a fourth co-author, C
Beglinger, based at University Hospital Basle,
Switzerland.
NOTICES
British Society of Gastroenterology
Paul Brown Travel Fellowships
The Paul Brown Travel Fellowships are
awarded by the Endoscopy Committee of
the BSG. They are intended to assist trainee
gastroenterologists and established consul-
tants in visits to units outside the United
Kingdom for specialist experience and train-
ing in endoscopy.
Specialist registrars who have not achieved
their CCST are expected to have the approval
of their Postgraduate Dean and their
Regional Training Director when they apply
for a Travel Fellowship. Applicants are
expected to provide confirmation that they
have been accepted for training in the unit
that they wish to visit.
Successful applicants will be expected to
provide a brief written report to the Endo-
scopy Committee of the outcome of their visit.
Application forms are available from the
British Society of Gastroenterology Office, 3




This conference will be held on 14–17
February 2004 in Hong Kong. The topic of
the conference is ‘‘Liver Diseases in the Post-
Genomic Era’’. Further details: Ms Kristie
Leung, Room 102–105 School of General
Nursing, Queen Mary Hospital, 102
Pokfulam Road, Hong Kong. Tel: +852 2818
4300/8101 2442; fax: +852 2818 4030; email:
kristieleung@hepa2004.org; website: www.
hepa2004.org
PET/CT and SPECT/CT Imaging in
Medical, Radiation, Surgical and
Nuclear Oncology
This continuing medical education pro-
gramme will take place on 19220 March
2004 at Johns Hopkins University School of
Medicine, Baltimore, Maryland, USA. Further
details: Office of Continuing Medical Educa-
tion, Johns Hopkins University School of
Medicine, Turner 20, 720 Rutland Avenue,
Baltimore, Maryland 21205-2195. Tel: +1 410
955 2959; fax:+1 410 955 0807; email: cmenet@
jhmi.edu; website: www.hopkinscme.org
39th Annual Meeting of the European
Association for the Study of the Liver
This meeting will be held on 15–19 April 2004
in Berlin, Germany. Further details:
Secretariat, c/o Kenes International, 17 rue
du Cendrier, PO Box 1726, CH-1211 Geneva,
Switzerland. Tel: +41 22 908 0488; fax: +41 22
732 2850; email: info@easl.ch; website:
www.easl.ch/easl2004
N Deadline for receipt of abstracts: 16
November 2003
N Deadline for early registration 10 February
2004
14th International Workshop of
Digestive Endoscopy,
Ultrasonography and Radiology
The 14th International Workshop of Digestive
Endoscopy, Ultrasonography and Radiology
will be held in Marseille on 27—28 May 2004.
For further information, please contact:
Nathalie Fontant, Atelier Phenix, 41 rue
Docteur Morruci, 13006 — Marseille (tel:
(33) 04-91-37-50-83; fax: (33) 04-91-57-15-
28; e-mail: nfontant@aphenix.com).
International Hans Popper Award
2003
This year the International Hans Popper
Award goes to Gut editorial board member,
Professor Scott Laurence Friedman of the
Mount Sinai School of Medicine in New York,
for his pioneering work on the pathogenesis
of hepatic fibrosis, which ultimately led to
the discovery of hepatic stellate cells.
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